



ADVIK LABORATORIES LIMITED

ALL/BSE/ASE/OUT-BM/Q1/1920/516

Dated: 12th August, 2019

To,

The Manager (Listing)

BSE Limited

1st Floor, P.J. Towers

Dalal Street, Mumbai – 400001

Sub: Outcome of the Board Meeting and Submission of Unaudited Financial Results for the quarter ended 30th June, 2019 as required u/r 33 of the SEBI (LODR) Regulations, 2015

Ref: BSE Scrip Code 531686; ASE Scrip Code- 01638 (ADVIK LABO)

Dear Sir,

This is to inform you that in pursuance to Regulation 33 of SEBI (LODR) Regulations, 2015, the Board of Directors of the Company in its meeting held on Monday 12th August, 2019 at 703, Arunachal Building, 19, Barakhamba Road, Connaught Place, New Delhi – 110001 and concluded just now has, inter-alia, transacted the following businesses:

1. Considered and Approved the Standalone Unaudited Financial Results of the Company for the quarter ended 30th June, 2019.
2. Considered and taken on records Limited Review Report submitted by the Statutory Auditors of the company on the Unaudited Financial Results of the Company for the quarter ended 30th June, 2019.
3. The Board also considered and took note of the OTS Sanction letter received from Indian Overseas Bank wherein the said Bank has approved the One Time Settlement offer for Rs. 8.30 Crore made by the Company to settle the loan obtained by the Company from the said Bank.

Further pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, a copy of the aforesaid Unaudited Financial Results for the quarter ended 30th June, 2019 alongwith Limited Review Report of the Statutory Auditors thereon is enclosed herewith for your kind perusal.

Kindly take the aforesaid information in your records.

Thanking you.

Yours Truly,

For ADVIK LABORATORIES LIMITED

(Pooja Chuni)

Company Secretary



Encl: As above

CC:

The Manager (Listing)

Ahmedabad Stock Exchange Limited

1st Floor, Kamdhenu Complex

Opp. Sahajanand College,

Panjara Pole, Ambawadi, Ahmedabad – 380015

CIN No. : L74899HR1994PLC038300

Corporate Office : 703, Arunachal Building, 19, Barakhamba Road, Connaught Place, New Delhi - 110001

Phones : 011-42424884, 43571040-45, Fax : 011-43571047

Regd. Office & Factory : 138, ROZ-Ka Meo, Industrial Area, Sohna - 122103 (Distt. Mewat), Haryana

Phones : 0124-2362471 **E-mail :** mail@advikindia.com **Website :** www.advikindia.com

ADVIK LABORATORIES LIMITED

Regd. Off. :138, Roz Ka Meo Industrial Area, Sohna, Distt. Mewat Haryana - 122103

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019

CIN : L74899HR1994PLC038300

| Sr No | Particulars | (Rs in Lacs except EPS) | | | |
|-------|--|--------------------------|------------------------|--------------------------|------------------------|
| | | Quarter ended | | | Year Ended |
| | | 30-Jun-19 (Unaudited) | 31-Mar-19 (Audited) | 30-Jun-18 (Unaudited) | 31-Mar-19 (Audited) |
| 1 | Income from Operation | | | | |
| | (a) Net Sales/Revenue from Operations | - | - | - | 82.44 |
| | (b) Other Operating Income | 0.44 | - | - | 0.37 |
| | (c) Other Income | 0.20 | 1.70 | - | 1.70 |
| | Total Income | 0.64 | 1.70 | - | 84.51 |
| 2 | Expenses | | | | |
| | a) Cost of Materials consumed | - | 0.06 | 0.28 | 0.34 |
| | b) Purchase of Stock-in-trade | - | - | 82.16 | 82.16 |
| | c) Changes in Inventory of Finished goods, Work-in-progress and Stock-in-trade | - | - | (82.16) | - |
| | d) Employee Benefits Expenses | 10.61 | 12.72 | 12.27 | 48.57 |
| | e) Finance Costs | 0.01 | 0.14 | 0.11 | 0.31 |
| | f) Depreciation and Amortisation expense | 14.64 | 14.69 | 14.70 | 58.79 |
| | g) Other expenses | 5.17 | 8.16 | 5.77 | 23.63 |
| | Total Expenses | 30.43 | 35.77 | 33.13 | 213.80 |
| 3 | Profit/(Loss) before Exceptional items and tax (1-2) | (29.79) | (34.07) | (33.13) | (129.29) |
| 4 | Exceptional Items | - | - | - | - |
| 5 | Profit/(Loss) before tax (3 + 4) | (29.79) | (34.07) | (33.13) | (129.29) |
| 6 | Tax Expenses | | | | |
| | - Current tax | - | - | - | - |
| | - Deferred tax | (2.27) | (0.68) | (1.34) | (4.69) |
| | Total Tax Expenses | (2.27) | (0.68) | (1.34) | (4.69) |
| 7 | Profit/(Loss) for the period (5-6) | (27.52) | (33.39) | (31.79) | (124.60) |
| 8 | Other Comprehensive Incomes | 0.33 | 0.03 | 0.43 | 1.32 |
| | Actuarial Gain/(-)loss on Defined Benefit plan | | | | |
| 9 | Total Comprehensive Income for the period (7+8) | (27.19) | (33.36) | (31.36) | (123.28) |
| 10 | Paid-up equity share capital (face value of Rs 10/- per share) | 1,911.14 | 1,911.14 | 1,911.14 | 1,911.14 |
| 11 | Earning per share (EPS) of Rs 10/- each (not annualized) | | | | |
| | (1) Basic | (0.14) | (0.17) | (0.17) | (0.65) |
| | (2) Diluted | (0.14) | (0.17) | (0.17) | (0.65) |

NOTES:-

| | |
|---|--|
| 1 | The above Financial Results for the quarter ended June 30, 2019 has been reviewed by the Audit Committee and thereafter approved by the Board of Directors & taken on record at its meeting held on August 12, 2019. A Limited review of the same has been carried out by the Statutory Auditors. |
| 2 | The Company operates in a single segment viz pharmaceuticals formulations and the results pertain to a single segment in accordance with IND AS 108-Operating Segment. |
| 3 | The Company has adopted Indian Accounting Standards ("Ind AS") notified by the Ministry of Corporate Affairs. This Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevent rules issued thereunder and other recognised accounting practices and policies to the extent applicable. |
| 4 | The format for un-audited quarterly results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with requirements of SEBI's circular dated July 5, 2016. IND AS and Schedule III (Division II) to the Companies Act, 2013-applicable to the companies that are required to comply with IND AS. |
| 5 | In the absence of any orders during the quarter under review, there is a decline in the operating activities of the company. The company is getting quotes from the prospective buyers & believes that the new deals would be finalized soon. |





| | |
|---|---|
| 6 | The Figures for the quarter ended March 31, 2019 represents the balancing figures between the audited figures for the year ended 31st March, 2019 and the published year to date figures for the 9 months ended December 31, 2018. |
| 7 | Auditor's Observation:- a) Due to default in payments of bank loans, the company's accounts have been classified as Non-Performing Assets (NPA) by the bank. Indian Overseas Bank has not charged interest on Cash credit & Term Loan Limits. During the period under review no provision has been made for such interest in the books of account of the company and to that extent bank's loan liability and total loss is understated by Rs. 594.02 lacs plus penal charges that the bank may charge. b) The company had recorded the cost of the investment at the face value of the equity shares issued and had not determined the fair value as required by IND AS. In the absence of the fair value of the securities acquired we are unable to express an opinion on the value of the investment recorded. |
| 8 | Our explanation to Auditor's Observation:- 1. The Company's accounts had become Non Performing Assets (NPA) with Indian Overseas Bank and due to this reason, IOB has stopped charging interest from the company on its outstanding debts. In view of the above, the company has not charged to statement of Profit & Loss account Interest expenses of Rs. 41.33 Lacs and related penal interest & other charges, if any, for the reported period, in respect of delay of repayments of borrowings from the bank. Further liability for interest exepnses of Rs.552.69 lacs till 31/03/2019 has not been accounted for. The company has made necessary efforts to reach One Time Settlement with Indian Overseas Bank & had sent the One Time Settlement proposal with Indian Overseas Bank which has been approved by the Bank. 2. The company has misplaced/lost the share certificates of the Investment made by it in unquoted equity shares of other companies during the shifting of its records. Hence these share certificates are not physically held by the company. The Company has sent various request letters to the companies in which it has made investments for issue of duplicate share certificates. However, till date the company has not received any reply from these companies. In order to ensure the compliance of IND AS in true letter and spirits, the company is also trying to ascertain the fair market value of its investments. |
| 9 | Previous year/period figures have been regrouped/arranged, wherever necessary to make them comparable with the current period figure. |

For and on behalf of Board of Directors

(Peeyush Kumar Aggarwal)
Chairman
DIN : 00090423



Place: New Delhi
Date : 12.08.2019



RMA & ASSOCIATES LLP

Chartered Accountants
LLPIN: AAI-9419 (ISO 9001:2015)

Address : A-13, Ground Floor, Lajpat
Nagar-III, New Delhi - 24

Phone : 011-49097836

Email : ca.jamit@gmail.com

Website : www.rma-ca.com

Independent Auditors Review Report on Quarterly Unaudited Standalone Financial Results of the company for the quarter ended June 30, 2019 (Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

The Board of Directors
Advik Laboratories Limited

We have reviewed the accompanying statement of unaudited Standalone financial results of **M/s Advik Laboratories Limited** for the quarter ended on 30th June, 2019 being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagements to "Review of Interim Financial Information performed by Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) under Section 133 of the Companies Act 2013 read the relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Except for the following:

- Due to default in payments of bank loans, the company's accounts have been classified as Non-Performing Assets (NPA) by the bank. Indian Overseas Bank has not charged interest on cash credit & Term Loan Limits. During the period under review no provision has been made for such interest in the books of account of the company and to that extent bank's loan liability and total loss is understated by Rs. 594.02 lacs plus penal charges that the bank may charges.
- The company had recorded the cost of the investment at the face value of the equity shares issued and had not determined the fair value as required by IND AS. In the absence of the fair value of the securities acquired we are unable to express as opinion on the value of the investment recorded.

For M/s. RMA & Associates LLP
Chartered Accountants
FRN: 000978N/N500062


Amit Jain
(Partner)
(Membership No. 503109)

UDIN : 19503109AAAAAN7762

Place : New Delhi
Date : 12/08/2019